Novavax says its COVID-19 vaccine appears 89% effective, based on early findings from a British study. According to USA Today, the two-dose vaccine was just 60% effective in the South African trial.
Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...
Hosted on MSN
Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda
Novavax, Inc. (NVAX) announced on Thursday that its COVID-19 vaccine, Nuvaxovid, has been approved in Japan, triggering a milestone payment from Japanese pharmaceutical company Takeda. The vaccine was ...
LONDON (AP) - Novavax Inc. said Thursday that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not quite as well — ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results